Lanthanum carbonate reduces urine phosphorus excretion: Evidence of high-capacity phosphate binding

Renal Failure

Volumn 34, Issue 3, 2012, Pages 263-270

  Pennick, Michael ^a   Poole, Lynne ^a   Dennis, Kerry ^a   Smyth, Michael ^b  

^a Shire Pharmaceuticals   (United Kingdom)

^b Modulus Medical   (United Kingdom)

Author keywords

Chronic kidney disease; Hyperphosphatemia; Lanthanum carbonate; Phosphate binder; Sevelamer hydrochloride

Indexed keywords

LANTHANUM CARBONATE; PHOSPHATE; PHOSPHORUS;

ABDOMINAL PAIN; ARTICLE; DRUG EFFICACY; DRUG TOLERABILITY; GASTROINTESTINAL ABSORPTION; HEADACHE; HUMAN; HUMAN EXPERIMENT; MORNING DOSAGE; NAUSEA; NORMAL HUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TABLET; URINARY EXCRETION; VOMITING;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERPHOSPHATEMIA; KIDNEY FAILURE, CHRONIC; LANTHANUM; MALE; PHOSPHORUS; PHOSPHORUS COMPOUNDS; PHOSPHORUS, DIETARY; REFERENCE VALUES; SINGLE-BLIND METHOD; YOUNG ADULT;

EID: 84857545484     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2011.649657     Document Type: Article

References (26)

1. Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000;342(20): 1478-1483. (Pubitemid 30318271)
2. Guerin AP, London GM, Marchais SJ, Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant. 2000;15(7):1014-1021. (Pubitemid 30410374)
3. Bellinghieri G, Santoro D, Savica V. Emerging drugs for hyperphosphatemia. Expert Opin Emerg Drugs. 2007;12(3): 355-365. (Pubitemid 47518373)
4. Albaaj F, Hutchison AJ. Lanthanum carbonate (Fosrenol): A novel agent for the treatment of hyperphosphataemia in renal failure and dialysis patients. Int J Clin Pract. 2005;59(9): 1091-1096.
5. Burke SK, Slatopolsky EA, Goldberg DI. RenaGel, a novel calcium- and aluminium-free phosphate binder, inhibits phosphate absorption in normal volunteers. Nephrol Dial Transplant. 1997;12(8):1640-1644. (Pubitemid 27346290)
6. Ketteler M, Rix M, Fan S, et al. Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis. Clin J Am Soc Nephrol. 2008;3(4):1125-1130.
7. Autissier V, Damment SJ, Henderson RA. Relative in vitro efficacy of the phosphate binders lanthanum carbonate and sevelamer hydrochloride. J Pharm Sci. 2007;96:2818-2827. (Pubitemid 47597830)
8. Hruska KA, Mathew S, Lund R, Qiu P, Pratt R. Hyperphosphatemia of chronic kidney disease. Kidney Int. 2008;74(2):148-157. (Pubitemid 351915080)
9. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15(8):2208-2218. (Pubitemid 39031360)
10. Danese MD, Belozeroff V, Smirnakis K, Rothman KJ. Consistent control of mineral and bone disorder in incident hemodialysis patients. Clin J Am Soc Nephrol. 2008;3(5):1423-1429.
11. Eknoyan G, Levin A, Levin NW. Bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(Suppl. 3):1-201.
12. Kidney Disease Outcomes Quality Initiative. KDOQI clinical practice guidelines for nutrition in chronic renal failure. Am J Kidney Dis. 2000;35(6):S17-S104.
13. Ramirez JA, Emmett M, White MG, et al. The absorption of dietary phosphorus and calcium in hemodialysis patients. Kidney Int. 1986;30(5):753-759. (Pubitemid 17049596)
14. Moshfegh A, Goldman J, Ahuja J, Rhodes D, LaComb R. What We Eat in America, NHANES 2005-2006: Usual Nutrient Intakes from Food and Water Compared to 1997 Dietary Reference Intakes for Vitamin D, Calcium, Phosphorus and Magnesium. Washington, DC: US Department of Agriculture, Agricultural Research Service; 2009.
15. Sherman RA, Mehta O. Phosphorus and potassium content of enhanced meat and poultry products: Implications for patients who receive dialysis. Clin J Am Soc Nephrol. 2009;4(8): 1370-1373.
16. Sheikh MS, Maguire JA, Emmett M, et al. Reduction of dietary phosphorus absorption by phosphorus binders. A theoretical, in vitro, and in vivo study. J Clin Invest. 1989;83(1): 66-73. (Pubitemid 19048406)
17. Gutierrez OM, Isakova T, Smith K, Epstein M, Patel N, Wolf M. Racial differences in postprandial mineral ion handling in health and in chronic kidney disease. Nephrol Dial Transplant. 2010;25(12):3970-3977.
18. Kimlin MG. Geographic location and vitamin D synthesis. Mol Aspects Med. 2008;29(6):453-461.
19. Sherman RA. Dietary phosphate restriction and protein intake in dialysis patients: A misdirected focus. Semin Dial. 2007;20(1):16-18.
20. Lau AH, Kuk JM, Franson KL. Phosphate-binding capacities of calcium and aluminum formulations. Int J Artif Organs. 1998;21(1):19-22.
21. Heinrich T, Heidt H, Hafner V, et al. Calcium load during administration of calcium carbonate or sevelamer in individuals with normal renal function. Nephrol Dial Transplant. 2008;23(9):2861-2867.
22. Shire Pharmaceuticals. FOSRENOL (lanthanum carbonate) rescribing Information. Wayne, PA: Shire US Inc.; 2011.
23. Genzyme Corporation. Renagel (sevelamer hydrochloride) Prescribing Information. Cambridge, MA: Genzyme Corporation; 2007.
24. Nabi Biopharmaceuticals. PhosLo (calcium acetate) Package Insert. Rockville, MD: Nabi Pharmaceuticals; 2003.
25. Chiu YW, Teitelbaum I, Misra M, de Leon EM, Adzize T, Mehrotra R. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin J Am Soc Nephrol. 2009;4(6):1089-1096.
26. Birge SJ, Peck WA, BermanM, Whedon GD. Study of calcium absorption in man: A kinetic analysis and physiologic model. J Clin Invest. 1969;48:1705-1713.